US20020193413A1 - Use of panaverium bromide for preventing cell proliferation and diseases caused thereby in the liver and digestive tract - Google Patents
Use of panaverium bromide for preventing cell proliferation and diseases caused thereby in the liver and digestive tract Download PDFInfo
- Publication number
- US20020193413A1 US20020193413A1 US09/180,305 US18030599A US2002193413A1 US 20020193413 A1 US20020193413 A1 US 20020193413A1 US 18030599 A US18030599 A US 18030599A US 2002193413 A1 US2002193413 A1 US 2002193413A1
- Authority
- US
- United States
- Prior art keywords
- tract
- diseases
- cancer
- medicament
- bromide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 12
- 201000010099 disease Diseases 0.000 title claims abstract description 11
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 title abstract description 3
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 210000004185 liver Anatomy 0.000 title abstract 2
- 239000003814 drug Substances 0.000 claims abstract description 12
- IKGXLCMLVINENI-QOXGANSBSA-M [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC Chemical compound [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC IKGXLCMLVINENI-QOXGANSBSA-M 0.000 claims description 31
- 229960002088 pinaverium bromide Drugs 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 12
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 208000010643 digestive system disease Diseases 0.000 claims description 5
- 206010020718 hyperplasia Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 206010020880 Hypertrophy Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000008719 thickening Effects 0.000 claims description 3
- 206010007270 Carcinoid syndrome Diseases 0.000 claims description 2
- 206010007275 Carcinoid tumour Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 230000004899 motility Effects 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 14
- 229960001722 verapamil Drugs 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 6
- 208000002458 carcinoid tumor Diseases 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 3
- JRHMPHMGOGMNDU-UHFFFAOYSA-N 2-(bromomethyl)-1-methoxy-4-nitrobenzene Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CBr JRHMPHMGOGMNDU-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000001955 intestinal smooth muscle cell Anatomy 0.000 description 3
- 229960000361 pinaverium Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DDHUTBKXLWCZCO-BVSLBCMMSA-N 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-[(1S,2S,5S)-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]ethoxy]ethyl]morpholin-4-ium Chemical compound C1=C(OC)C(OC)=CC(Br)=C1C[N+]1(CCOCC[C@H]2[C@@H]3C[C@@H](C3(C)C)CC2)CCOCC1 DDHUTBKXLWCZCO-BVSLBCMMSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102100030511 Stanniocalcin-1 Human genes 0.000 description 2
- 101710142157 Stanniocalcin-1 Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 208000035984 Colonic Polyps Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- DDHUTBKXLWCZCO-UHFFFAOYSA-N pinaverium Chemical compound C1=C(OC)C(OC)=CC(Br)=C1C[N+]1(CCOCCC2C3CC(C3(C)C)CC2)CCOCC1 DDHUTBKXLWCZCO-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- inhibition of the proliferation of neoplastic cells is a determining factor in the prevention and treatment of cancers and metastases of the digestive tract.
- This compound may also be used for the therapeutic treatment of hepatocarcinoma or of cancer of the pancreas and, more generally, of any cancer of the hepatodigestive tract.
- the present invention therefore relates to the use of pinaverium bromide for preparing a medicament which is intended for preventing or treating diseases of the hepatodigestive tract which are due to excessive proliferation of the cells of the tract.
- the invention also comprises a method for the prophylactic or therapeutic treatment of diseases of the hepatodigestive tract which are due to excessive proliferation of the cells of the tract, which method consists in administering a medicament containing pinaverium bromide, as the active principle, to a patient.
- Pinaverium bromide (or verapamil), dissolved in 50% ethanol or DMSO, is added to the cell culture at various concentrations, and the percentage inhibition of cell proliferation is assessed by measuring the incorporation of tritiated thymidine ( 3 HThdR), with the latter being added to each well at the rate of 37 KBq (1 ⁇ Ci); the contents of the wells are withdrawn and counted 15 hours later using a “Filter MateTM Cell Harvester and Matrix 9600TM Direct Beta Counter” (Packard).
- 3 HThdR tritiated thymidine
- the inhibitory effect of the pinaverium bromide is from 3 to 5 times greater than that of the verapamil.
- the STC-1 mouse intestinal cancer cell lines are cultured in a DMEM medium which contains 15% horse serum and 2.5% FCS.
- the products to be studied are added to the culture and cell growth is assessed by counting cells or, more frequently, by a fluorescence technique which is based on the cellular enzymic hydrolysis of the fluorogenic substrate 4-methylumbelliferyl heptanoate (MUH); thus, viable cells which are incubated with MUH generate a fluorescent signal which is proportional to their number and which is determined using a “Titentec Fluoroscan II” (Flow Laboratory), with the value being given in arbitrary fluorescence units.
- a fluorescence technique which is based on the cellular enzymic hydrolysis of the fluorogenic substrate 4-methylumbelliferyl heptanoate (MUH)
- Pinaverium bromide was found to be twice as active as verapamil in the test.
- Pinaverium bromide is injected intraperitoneally a few hours before injecting the HT29 cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The use of panaverium bromide for preparing a drug for treating or preventing diseases of the liver and digestive tract caused by excessive cell proliferation therem, is disclosed.
Description
- The present invention relates to a novel use of pinaverium bromide in gastrointestinal pathologies, inflammatory digestive diseases (IBD), colites, ulcers, Crohn's disease or functional colopathies (IBS), during which proliferative phenomena which lead to pathological complications appear.
- While the constant and rapid renewal of the epithelium of the digestive tract is an important factor in the maintenance of the integrity of the mucous membrane, it is also an important factor in the development of tumours and hypertrophies.
- In these latter cases, an abnormal proliferation of the epithelial cells and an increased number of proliferative zones are always observed; this is also found in patients who are at familial risk of cancer of the colon or in patients who are suffering from diseases which predispose to cancer of the digestive tract (chronic gastrites, inflammatory digestive diseases, Crohn's disease, ulcerative colites, colonic polyps, etc.). Furthermore, it has been shown that inflammation of the intestine can give rise to hypertrophy and hyperplasia of the smooth muscle cells at one and the same time. This results in a thickening of the muscle wall, and therefore in a change in its motility, resulting in the appearance of complications which require surgical treatments.
- In addition, inhibition of the proliferation of neoplastic cells is a determining factor in the prevention and treatment of cancers and metastases of the digestive tract.
- Pinaverium bromide is the only calcium antagonist which is selective for the intestinal tract and which has spasmolytic activity and which is prescribed for the chronic treatment of functional digestive disorders (irritable bowel syndrome or IBS). This compound has been described, in particular, in French patent 2 097 032.
- The authors of the present invention have now surprisingly demonstrated, by means of studies carried out in vitro, that pinaverium bromide is able to inhibit the proliferation of neoplastic and hyperplastic cells of the digestive tract, with this inhibition being greater than that brought about by another calcium antagonist, i.e. verapamil. Furthermore, a study carried out in vivo also demonstrated the efficacy of pinaverium bromide in decreasing tumours induced in animals.
- Pinaverium bromide can therefore be used as a medicament for preventing cancer of the digestive tract both in the healthy individual and the individual suffering from a digestive pathology such as IBS. In the latter individual, it will then exert a prophylactic or therapeutic effect which complements its effect on the IBS.
- This compound may also be used for the therapeutic treatment of hepatocarcinoma or of cancer of the pancreas and, more generally, of any cancer of the hepatodigestive tract.
- The present invention therefore relates to the use of pinaverium bromide for preparing a medicament which is intended for preventing or treating diseases of the hepatodigestive tract which are due to excessive proliferation of the cells of the tract.
- More especially, the invention relates to the use of pinaverium bromide for preparing a medicament which is intended for preventing or treating intestinal cellular hyperplasias which are linked to inflammatory digestive diseases, or for preventing hypertrophies of the smooth-muscle-cell wall of the intestinal tract and motor disturbances which are due to the inflammatory diseases of the digestive tract (inflammatory bowel disease or IBD, Crohn's disease or ulcerative colitis) which are characteristic of the IBS.
- The invention is also directed towards using pinaverium bromide for preparing a medicament which is intended for preventing or treating a cancer of the hepatodigestive tract, comprising cancer of the colon and of the stomach, hepatocarcinoma and cancer of the pancreas, or else the carcinoid syndrome or functional diseases which are linked to the carcinoid tumours.
- It also relates to the use of pinaverium bromide for preparing a medicament which is intended for preventing and treating cancer of the hepatodigestive tract in patients who are suffering from irritable syndromes of the colon (irritable bowel syndrome or IBS), while effecting a complementary and simultaneous treatment of the symptoms which are characteristic of the IBS.
- The invention also comprises a method for the prophylactic or therapeutic treatment of diseases of the hepatodigestive tract which are due to excessive proliferation of the cells of the tract, which method consists in administering a medicament containing pinaverium bromide, as the active principle, to a patient.
- Finally, the method is directed towards using pinaverium bromide for producing a medicament which is intended for treating inflammatory digestive diseases such as IBD (inflammatory intestinal disease or inflammatory bowel disease), Crohn's disease or ulcerative colitis, which diseases are generally associated with the thickening of the mucous membrane.
- Preferably, within the context of the present invention, the pinaverium bromide is used by being administered in a daily quantity of between 50 mg and 450 mg. Administration is by the oral route or by the injectable route, using a solution which is dosed at from 0.2 to 1 mg/ml.
- The advantages of the invention emerge in more detail in the tests which are described below.
- In addition, the following figure shows the effect of pinaverium bromide (▪) on inhibition of the growth of pancreatic carcinoid cells as compared with the effect of verapamil (⋄).
- Test 1:
- Inhibition of the proliferation of colon cancer cells by pinaverium bromide as compared with the inhibition induced by another calcium inhibitor (verapamil)
- The HT29 colon cancer cell line employed (originally isolated from an adenocarcinoma of the human colon) was obtained from the ATCC (American Type Culture Collection).
- The cells are cultured at the rate of 10 4 or 5×104 cells in a well containing 200 μl of culture medium composed of RPMI 1460 supplemented with 10% fetal calf serum, 2 mM of L-glutamine and 25 μM gentamicin. Pinaverium bromide (or verapamil), dissolved in 50% ethanol or DMSO, is added to the cell culture at various concentrations, and the percentage inhibition of cell proliferation is assessed by measuring the incorporation of tritiated thymidine (3HThdR), with the latter being added to each well at the rate of 37 KBq (1 μCi); the contents of the wells are withdrawn and counted 15 hours later using a “Filter Mate™ Cell Harvester and Matrix 9600™ Direct Beta Counter” (Packard).
- The results are as follows:
Concentration of % Inhibition the product tested pinaverium % Inhibition (% by weight) bromide verapamil 3HThdR 0.025 78 17 0.05 82 17 0.1 86 27 - The inhibitory effect of the pinaverium bromide is from 3 to 5 times greater than that of the verapamil.
- Test 2:
- Effect of pinaverium bromide on hepatocarcinoma cells.
- LFC rat hepatocarcinoma cells (VPR42, Villejuif) are cultured at the rate of 10 4 or 5×104 cells in a well containing 200 μl of culture medium. The products to be tested (pinaverium bromide and verapamil) are dissolved in 50% ethanol and used at concentrations of 0.1% and 1% by weight.
- Inhibition of cell proliferation is assessed using tritiated thymidine as described in Test 1. The assessment is made in comparison with the reference product, which is verapamil. The results show a percentage inhibition of proliferation of from 85 to 88% in the case of pinaverium bromide and of 72% in the case of verapamil.
- Test 3:
- Effect of Pinaverium Bromide on the Growth of STC-1 Carcinoid Intestinal Cells
- The STC-1 mouse intestinal cancer cell lines are cultured in a DMEM medium which contains 15% horse serum and 2.5% FCS. The products to be studied are added to the culture and cell growth is assessed by counting cells or, more frequently, by a fluorescence technique which is based on the cellular enzymic hydrolysis of the fluorogenic substrate 4-methylumbelliferyl heptanoate (MUH); thus, viable cells which are incubated with MUH generate a fluorescent signal which is proportional to their number and which is determined using a “Titentec Fluoroscan II” (Flow Laboratory), with the value being given in arbitrary fluorescence units.
- Pinaverium bromide was found to be twice as active as verapamil in the test.
- (ED50 PINAVERIUM=7 μM ; ED50 VERAPAMIL=13 μM)
- Test 4:
- Study of the Inhibition by Pinaverium Bromide of the Growth of BON Pancreatic Carcinoid Cells
- The BON human pancreatic carcinoid cell lines are cultured in a DMEM/F12K (1/1) medium to which 10% FCS is added. The verapamil and the pinaverium bromide are added to the culture and cell growth is determined after 8 days by means of a fluorescence technique such as that described in Test 3.
- The results reported in the figure demonstrate the efficacy of pinaverium bromide in inhibiting the growth of the BON pancreatic carcinoid cells, and its superiority to verapamil
- (ED50 PINAVERIUM=7.2 μM ; ED50 VERAPAMIL=43.6 μM).
- Test 5:
- Inhibition by Pinaverium Bromide of the Hyperplasia of Rat Intestinal Smooth Muscle Cells Which is Induced by PDGF (Platelet-derived Growth Factor)
- The intestinal smooth muscle cells are cultured in a culture medium containing 10% fetal bovine serum and then exposed to PDGF (growth factor found during inflammations) for 20 hours. Cell growth is assessed by the incorporation of tritiated thymidine.
- Pinaverium bromide (10 −5 M) totally inhibits the growth of the intestinal smooth muscle cells which is induced by the inflammation factor PDGF. It therefore has a beneficial effect on inflammation phenomena of the digestive tract.
- Test 6:
- Effect of Pinaverium Bromide on the Diameters of the Tumours which are Induced in Nude Mice.
- The tumours are induced by subcutaneously injecting HT29 colon cancer cells into nude mice.
- Pinaverium bromide is injected intraperitoneally a few hours before injecting the HT29 cells.
- Tumour development is assessed by measuring the diameter of the induced local tumour in relation to the duration of the experiment, which is 44 days.
- A 30% reduction in the diameter of the tumours is observed from the 25th day of the experiment onwards.
Claims (6)
1. Use of pinaverium bromide for preparing a medicament which is intended for preventing or treating diseases of the hepatodigestive tract which are due to excessive proliferation of the cells of the tract.
2. Use according to claim 1 , characterized in that the diseases of the hepatodigestive tract are intestinal cellular hyperplasia or hypertrophy of the smooth-muscle-cell wall of the intestinal tract and motility disturbances which are due to the inflammatory diseases of the digestive tract (inflammatory bowel disease or IBD, Crohn's disease or ulcerative colitis) which are characteristic of the irritable syndromes of the colon (IBS).
3. Use according to claim 1 for preparing a medicament which is intended for preventing or treating a cancer of the hepatodigestive tract, comprising cancer of the colon and of the stomach, hepatocarcinoma and cancer of the pancreas, or else the carcinoid syndrome or functional diseases which are linked to the carcinoid tumours.
4. Use according to claim 1 for preparing a medicament which is intended for preventing and treating cancer of the hepatodigestive tract in patients who are suffering from irritable syndromes of the colon (irritable bowel syndrome or IBS), while effecting a complementary and simultaneous treatment of the symptoms which are characteristic of the IBS.
5. Use of pinaverium bromide for producing a medicament which is intended for treating inflammatory digestive diseases, such as inflammatory intestinal disease (inflammatory bowel disease or IBD), Crohn's disease or ulcerative colitis, which diseases are generally associated with thickening of the mucous membrane.
6. Use according to claim 1 in which pinaverium bromide is used in sufficient quantity to be administered, by the oral route or by the injectable route, at the rate of from 50 to 450 mg per day using a solution which is dosed at from 0.2 to 1 mg/ml.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9605640A FR2748206B1 (en) | 1996-05-06 | 1996-05-06 | USE OF PINAVERIUM BROMIDE FOR THE PREVENTION OF PROLIFERATIVE PHENOMENA OF HEPATODIGESTIVE TRACT CELLS AND THE DISEASES THEREOF |
| FR96/05640 | 1996-05-06 | ||
| PCT/FR1997/000809 WO1997041859A1 (en) | 1996-05-06 | 1997-05-06 | Use of panaverium bromide for preventing cell proliferation and diseases caused thereby in the liver and digestive tract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20020193413A1 true US20020193413A1 (en) | 2002-12-19 |
| US6500826B1 US6500826B1 (en) | 2002-12-31 |
Family
ID=9491870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/180,305 Expired - Lifetime US6500826B1 (en) | 1996-05-06 | 1997-05-06 | Use of panaverium bromide for preventing cell proliferation and diseases caused thereby in the liver and digestive tract |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6500826B1 (en) |
| EP (1) | EP0900084B1 (en) |
| AU (1) | AU2902397A (en) |
| BR (1) | BR9709219A (en) |
| CA (1) | CA2254395C (en) |
| ES (1) | ES2236806T3 (en) |
| FR (1) | FR2748206B1 (en) |
| HU (1) | HU225886B1 (en) |
| PT (1) | PT900084E (en) |
| WO (1) | WO1997041859A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080214445A1 (en) * | 2005-06-23 | 2008-09-04 | Sebastien Bihorel | Method of Treating a Solid Tumor Disease Comprising Administering a Combination Comprising Imatinib and an Inhibitor of an Efflux Pump Active at the Blood Brain Barrier or Demethyl Imatinib |
| EP2020234A4 (en) * | 2006-03-09 | 2010-07-21 | Espinosa Abdala Leopoldo De Je | SYNERGISTIC COMBINATION OF L-TYPE CALCIC INHIBITORS WITH SELECTIVE ACTION ON THE GASTROINTESTINAL TRACT AND INERT SILICONE |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040244062A1 (en) * | 2003-06-02 | 2004-12-02 | Crittenden Jill R. | Use of protein inhibitors as antithrombotic agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2097032B1 (en) * | 1970-07-29 | 1973-08-10 | Berri Balzac | |
| DE3922387A1 (en) * | 1989-07-07 | 1991-01-17 | Kali Chemie Pharma Gmbh | N-BENZYL-N - ((1S, 5S) -6,6-DIMETHYLBICYCLO / 3.1.1 / HEPT-2-YLAETHOXY-AETHYL) -MORPHOLINIUM SALTS CONTAINING GASTROPROTECTIVELY ACTIVE PHARMACEUTICAL PREPARATIONS |
-
1996
- 1996-05-06 FR FR9605640A patent/FR2748206B1/en not_active Expired - Fee Related
-
1997
- 1997-05-06 EP EP97923146A patent/EP0900084B1/en not_active Expired - Lifetime
- 1997-05-06 AU AU29023/97A patent/AU2902397A/en not_active Abandoned
- 1997-05-06 US US09/180,305 patent/US6500826B1/en not_active Expired - Lifetime
- 1997-05-06 HU HU9902593A patent/HU225886B1/en unknown
- 1997-05-06 BR BR9709219A patent/BR9709219A/en not_active Application Discontinuation
- 1997-05-06 CA CA002254395A patent/CA2254395C/en not_active Expired - Lifetime
- 1997-05-06 PT PT97923146T patent/PT900084E/en unknown
- 1997-05-06 ES ES97923146T patent/ES2236806T3/en not_active Expired - Lifetime
- 1997-05-06 WO PCT/FR1997/000809 patent/WO1997041859A1/en not_active Ceased
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080214445A1 (en) * | 2005-06-23 | 2008-09-04 | Sebastien Bihorel | Method of Treating a Solid Tumor Disease Comprising Administering a Combination Comprising Imatinib and an Inhibitor of an Efflux Pump Active at the Blood Brain Barrier or Demethyl Imatinib |
| EP2020234A4 (en) * | 2006-03-09 | 2010-07-21 | Espinosa Abdala Leopoldo De Je | SYNERGISTIC COMBINATION OF L-TYPE CALCIC INHIBITORS WITH SELECTIVE ACTION ON THE GASTROINTESTINAL TRACT AND INERT SILICONE |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997041859A1 (en) | 1997-11-13 |
| EP0900084B1 (en) | 2005-03-30 |
| PT900084E (en) | 2005-08-31 |
| AU2902397A (en) | 1997-11-26 |
| FR2748206A1 (en) | 1997-11-07 |
| ES2236806T3 (en) | 2005-07-16 |
| EP0900084A1 (en) | 1999-03-10 |
| CA2254395A1 (en) | 1997-11-13 |
| CA2254395C (en) | 2007-10-23 |
| HU225886B1 (en) | 2007-11-28 |
| BR9709219A (en) | 1999-08-10 |
| HUP9902593A2 (en) | 2000-02-28 |
| HUP9902593A3 (en) | 2000-04-28 |
| FR2748206B1 (en) | 1998-07-31 |
| US6500826B1 (en) | 2002-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ghia et al. | The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model | |
| EP2586443B1 (en) | Antitumor agent using compounds having kinase inhibitory effect in combination | |
| US20080242591A1 (en) | Methods of reducing angiogenesis | |
| Travis et al. | Optimum dose of olsalazine for maintaining remission in ulcerative colitis. | |
| EP3638233B1 (en) | Tinostamustine for use in treating ovarian cancer | |
| US20100266590A1 (en) | Combination therapy | |
| Green et al. | comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months | |
| Hall et al. | Methotrexate treatment for advanced bladder cancer | |
| CN113082039B (en) | Composition for treating sorafenib drug-resistant tumor and application thereof | |
| US6500826B1 (en) | Use of panaverium bromide for preventing cell proliferation and diseases caused thereby in the liver and digestive tract | |
| CN110290787B (en) | Composition for inhibiting metastasis of cancer and treating cancer | |
| US20210038696A1 (en) | Rectal insulin for treatment of inflammatory bowel diseases | |
| Vigliani et al. | The effects of BAL on the metabolism of lead and on the symptomatology in lead intoxication | |
| Burtin et al. | Decreased skin response to intradermal histamine in cancer patients | |
| US20030139373A1 (en) | Method for cancer therapy | |
| WO2018056620A1 (en) | Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a vda and topoisomerase inhibitor | |
| BR112020020758A2 (en) | FRACTIONAL DOSAGE OF A PHOSPHOLIPID ETHER ANALOG FOR CANCER TREATMENT | |
| KR20190094765A (en) | Composition for inhibiting metastasis and treating of cancer | |
| CN115518067A (en) | Medicine related to tumor treatment | |
| KR20240138069A (en) | Pharmaceutical composition for combined administration with anticancer agent containing phthalazinone derivative | |
| Kondás et al. | Local Adriamycin treatment for prevention of recurrence of superficial bladder tumours | |
| KR20220145757A (en) | Composition for inhibiting metastasis and treating of cancer | |
| CN119733054A (en) | A pharmaceutical composition for treating cancer and its application | |
| CN117398385A (en) | Composition for inhibiting cancer metastasis and treatment | |
| CN113633632A (en) | Application of siponimod in preparation of anti-tumor metastasis drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: SOLVAY PHARMA, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHRISTEN, MARIE-ODILE;MAUGARD, JOELLE;DUC, HUYNH;AND OTHERS;REEL/FRAME:010391/0540;SIGNING DATES FROM 19981104 TO 19990201 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| AS | Assignment |
Owner name: SOLVAY PHARMA (SAS), FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOLVAY PHARMA;REEL/FRAME:015232/0990 Effective date: 20040624 |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| AS | Assignment |
Owner name: ABBOTT PRODUCTS SAS, FRANCE Free format text: CHANGE OF NAME;ASSIGNOR:SOLVAY PHARMA (SAS);REEL/FRAME:032909/0250 Effective date: 20140416 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |